RAPT Therapeutics (RAPT Therapeutics) Margin of Safety % (DCF Earnings Based) : N/A (As of May. 24, 2024)

View and export this data going back to 2019. Start your Free Trial

What is RAPT Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

RAPT Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of RAPT Therapeutics's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, RAPT Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RAPT Therapeutics's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RAPT Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where RAPT Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.

RAPT Therapeutics Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of RAPT Therapeutics's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

RAPT Therapeutics (RAPT Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RAPT Therapeutics Inc (NAS:RAPT) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

0RA:Germany

Address

561 Eccles Avenue, South San Francisco, CA, USA, 94080

Website

https://www.rapt.com

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Executives

Dirk G. Brockstedt	officer: Chief Scientific Officer	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
William Ho	officer: Chief Medical Officer	561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA 94080
Wendye Robbins	director	C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA 94080
Column Group Ii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tcg Iv Gp, Llc	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv-a, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Rodney Kb Young	officer: Chief Financial Officer	STEMCELLS, INC., 3155 PORTER DRIVE, PALO ALTO CA 94304
Lori Lyons-williams	director	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Column Group Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Ii Management, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital Ii, Lp	10 percent owner	1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158